343-10-2

Basic information

• Product Name: 6-FLUORO-4-HYDROXYQUINOLINE-3-CARBOXYLIC ACID
• Synonyms: TIMTEC-BB SBB010209;6-FLUORO-4-HYDROXYQUINOLINE-3-CARBOXYLIC ACID;BUTTPARK 18\09-70;3-quinolinecarboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-;6-fluoro-4-hydroxyquinoline-3-carboxylic acid(SALTDATA: FREE);3-Carboxy-6-fluoro-4-hydroxyquinoline;3-Quinolinecarboxylic acid, 6-fluoro-4-hydroxy-;6-fluoro-4-hydroxy-3-Quinolinecarboxylic acid
• CAS NO: 343-10-2
• Molecular Formula: C₁₀H₆FNO₃
• Molecular Weight: 207.16
• Product Categories: Acids and Derivatives;Heterocycles
• Mol File: 343-10-2.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 362.7 °C at 760 mmHg
• Flash Point: 173.2 °C
• Appearance: /
• Density: 1.517 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 6-FLUORO-4-HYDROXYQUINOLINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 6-FLUORO-4-HYDROXYQUINOLINE-3-CARBOXYLIC ACID(343-10-2)
• EPA Substance Registry System: 6-FLUORO-4-HYDROXYQUINOLINE-3-CARBOXYLIC ACID(343-10-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 343-10-2(Hazardous Substances Data)

Usage

General Description

6-Fluoro-4-hydroxyquinoline-3-carboxylic acid is a complex organic compound that features in the biochemistry and organic chemistry fields. It incorporates several functional groups, including a carboxylic acid group, a hydroxyl group, and a fluoro group, located on a quinoline backbone. The structure and the presence of these groups indicate that the compound may exhibit unique chemical properties and may potentially serve as an important intermediate in the synthesis of other complex chemicals or drugs. Studies relating to this chemical are largely scientific and exploratory, requiring advanced knowledge in organic chemistry and potentially biochemistry.

Upstream product

• 71083-00-6 ethyl 6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
• 371-40-4 4-fluoroaniline 
• 26832-96-2 diethyl 2-(4-fluoroanilino)methylenemalonate 
• 318-35-4 ethyl 6-fluoro-4-hydroxy-3-quinoline-carboxylate 
• 144216-13-7 6-fluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid methyl ester 
• 251986-57-9 4,5-dimethoxycarbonyl-1-(4'-fluorophenyl)-1H-pyrrole-2,3-dione 
• 251986-69-3 6-fluoro-4-oxo-1,4-dihydro-quinoline-2,3-dicarboxylic acid 3-methyl ester 
• 251986-63-7 dimethyl 6-fluoro-4-oxo-1,4-dihydroquinoline-2,3-dicarboxylate 
• 251986-49-9 methyl 3-carbomethoxy-3-(4'-fluorophenyl)amino-2-propenoate 

Downstream Products

• 391-78-6 6-Fluoro-4-hydroxyquinoline 
• 873051-19-5 N-(2,4-di-tert-butyl-5-hydroxyphenyl)-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxamide 
• 103802-26-2 N,4-dihydroxy-6-fluoro-N-phenyl-3-quinoline carboxamide 
• 391-77-5 4-Chloro-6-fluoroquinoline 

Relevant articles and documents

Polysubstituted quinolone compounds, and preparation method and use thereof

The invention provides polysubstituted quinolone compounds, and a preparation method and a use thereof, and concretely provides a polysubstituted quinolone compound represented by formula I, and optical isomers, pharmaceutically acceptable salts or solvates thereof. All groups in the formula I are defined in the description. The quinolone compound has excellent c-Met inhibition activity, and can be used for treating c-Met activity or expression level corrected diseases.

Synthesis and biological evaluation of 4-oxoquinoline-3-carboxamides derivatives as potent anti-fibrosis agents

Thirty-one 4-oxoquinoline-3-carboxamides derivatives were synthesized and evaluated for their anti-fibrotic activities by the inhibition of TGF-β1-induced total collagen accumulation and anti-inflammatory activities by the inhibition of LPS-stimulated TNF-α production. Among them, three compounds (10a, 10l and 11g) exhibited potent inhibitory effects on both TGF-β1-induced total collagen accumulation and LPS-stimulated TNF-α production. Furthermore, oral administrations of 10l at a dose of 20 mg/kg/day for 4 weeks effectively alleviated lung inflammation and injury, and decreased lung collagen accumulation in bleomycin-induced pulmonary fibrosis model. Histopathological evaluation of lung tissue confirmed 10l as a potential, orally active agent for the treatment of pulmonary fibrosis.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.